AbCellera Biologics Intangible Assets

The latest intangible assets for ABCL is $37M as of March 2026. That compares with $41M in the prior-year period — down 9.1% year over year. Investors often review this figure alongside AbCellera Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ABCL's intangible assets moved from $41M to $37M — a 9.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AbCellera Biologics's operating scale or balance-sheet position.

A intangible assets figure of $37M for ABCL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ABCL's intangible assets ($37M), review year-over-year change from $41M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.